LU 51198, a highly sulfated, low-molecular-weight heparin derivative, prevents complement-mediated myocardial injury in the perfused rabbit heart

Journal of Pharmacology and Experimental Therapeutics

Volumn 282, Issue 2, 1997, Pages 554-560

  Gralinski, Michael R ^a   Park, James L ^a   Ozeck, Mark A ^a   Wiater, Bridget C ^a   Lucchesi, Benedict R ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOW MOLECULAR WEIGHT HEPARIN; LU 51198; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; HEART MUSCLE INJURY; HEART PERFUSION; HEMODYNAMIC MONITORING; HEPARINIZATION; MALE; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; RABBIT;

ANIMALS; COMPLEMENT INACTIVATOR PROTEINS; COMPLEMENT SYSTEM PROTEINS; CREATINE KINASE; HEART; HEMODYNAMIC PROCESSES; HEPARIN; HUMANS; MALE; MOLECULAR WEIGHT; MYOCARDIUM; POTASSIUM; RABBITS;

EID: 0030872502     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. BALDWIN, W. M. 3RD, PRUITT, S. K., BRAUER, R. B., DAHA, M. R. AND SANFILIPPO, F.: Complement in organ transplantation: Contributions to inflammation, injury and rejection. Transplantation 59: 797-808, 1995.
2. BLACK, S. C., GRALINSKI, M. R., FRIEDRICHS, G. S., KILGORE, K. S., DRISCOLL, E. M. AND LUCCHESI, B. R.: Cardioprotective effects of heparin or N-acetylheparin in an in vivo model of myocardial ischaemic and reperfusion injury. Cardiovasc. Res. 29: 629-636, 1995.
3. BOACKLE, R. J., CAUGHMAN, G. B., VESELY, J., MEDGYESI, G. AND FUDENBERG, H. H.: Potentiation of factor H by heparin: A Rate-limiting mechanism for inhibition of the alternative complement pathway. Mol. Immunol. 20: 1157-1164, 1983.
4. ECKER, E. E. AND GROSS, P.: Anticomplementary power of heparin. J. Infect. Dis. 44: 250-253, 1929.
5. FRIEDRICHS, G. S., KILGORE, K. S., MANLEY, P. J., GRALINSKI, M. R. AND LUCCHESI, B. R.: Effects of heparin and N-acetyl heparin on ischemia/reperfusion-induced alterations in myocardial function in the rabbit isolated heart. Circ. Res. 75: 701-710, 1994.
6. GRALINSKI, M. R., BLACK, S. C., STANCATO, L. F., KILGORE, K. S., CAMPAU, P. A., PARK, J. L., OZECK, M. J., PRATT, W. B. AND LUCCHESI, B. R.: Heat stress protects the perfused rabbit heart from complement-mediated injury. Am. J. Physiol. 271: H571-H578, 1996a.
7. GRALINSKI, M. R., DRISCOLL, E. M., FRIEDRICHS, G. S., DENARDIS, M. AND LUCCHESI, B. R.: Reduction in myocardial necrosis following glycosaminoglycan administration: Effects of a single intravenous administration of heparin or N-acetylheparin two hours prior to regional ischemia and reperfusion. J. Cardiovasc. Pharmacol. Ther. 1: 219-228, 1996c.
8. GRALINSKI, M. R., WIATER, B. C., ASSENMACHER, A. N. AND LUCCHESI, B. R.: Selective inhibition of the alternative complement pathway by sCR1[desLHR-A] protects the perfused isolated rabbit heart from human complement-mediated damage. Immunopharmacology. 34: 79-88, 1996b.
9. HOMEISTER, J. W., SATOH, P. AND LUCCHESI, B. R.: Effects of complement activation in the isolated heart: Role of the terminal complement components. Circ. Res. 71: 303-319, 1992.
10. KOISTINEN, V.: Effects of sulphated polyanions on functions of complement factor H. Mol. Immunol. 30: 113-118, 1993.
11. MAILLET, F., PETITOU, M., CHOAY, J. AND KAZATCHKINE, M. D.: Structure-function relationships in the inhibitory effect of heparin on complement activation: Independency of the anti-coagulant and anti-complementary sites on the heparin molecule. Mol. Immunol. 25: 917-923, 1988.
12. MERI, S. AND PANGBURN, M. K.: Discrimination between activators and nonactivators of the alternative pathway of complement: Regulation via a sialic acid/polyanion binding site on factor H. Proc. Natl. Acad. Sci. U.S.A. 87: 3982-3986, 1990.
13. MERI, S. AND PANGBURN, M. K.: Regulation of alternative pathway complement activation by glycosaminoglycans: Specificity of the polyanion binding site on factor H. Biochem. Biophys. Res. Commun. 198: 52-59, 1994.
14. PANGBURN, M. K., ATKINSON, M. A. AND MERI, S.: Localization of the heparin-binding site on complement factor H. J. Biol. Chem. 266: 16847-16853, 1991.
15. PLATTS-MILLS, T. A. E. AND ISHIZAKA, K.: Activation of the alternative pathway of human complement by rabbit cells. J. Immunol. 113: 248-358, 1974.
16. POLHILL, R. B. AND PRUITT, K. M. JR.: Kinetic assessment of alternative complement pathway activity in a hemolytic sytem. I. Experimental and mathematical analysis. J. Immunol. 121: 360-370, 1978.
17. RAEPPLE, E., HILL, H. U. AND Loos, M.: Mode of interaction of different polyanions with the first (C1, C1), the second (C2) and the fourth (C4) component of complement. I. Effect on fluid phase C1 and on C1 bound to EA or to EAC4. Immunochemistry 13: 251-255, 1976.
18. RASHMIR-RAVEN, A. M., COYNE, C. P., FENWICK, B. W., GAUGHAN, E. M., ANDREWS, G. A. AND DEBOWES, R. M.: Inhibition of equine complement activity by polysulfated glycosaminoglycans. Am. J. Vet. Res. 53: 87-90, 1992.
19. SEEGER, W., HARTMANN, R., NEUHOFF, H. AND BHAKDI, S.: Local complement activation, thromboxane-mediated vasoconstriction and vascular leakage in isolated lungs: Role of the terminal complement sequence. Am. Rev. Respir. Dis. 139: 88-99, 1989.
20. SEIFERT, P. S. AND KAZATCHKINE, M. D.: The complement system in atherosclerosis. Atherosclerosis 73: 91-104, 1988.
21. SHARATH, M. D., MERCHANT, Z. M., KIM, Y. S., RICE, K. G., LINHARDT, R. J. AND WEILER, J. M.: Small heparin fragments regulate the amplification pathway of complement. Immunopharmacology 9: 73-80, 1985.
22. SMILEY, J. D. AND MOORE, S. E. JR.: Immune-complex vasculitis: role of complement and IgG-Fc receptor functions. Am. J. Med. Sci. 298: 267-277, 1989.
23. WEILER, J. M., EDENS, R. E., LINHARDT, R. J. AND KAPELANSKI, D. P.: Heparin and modified heparin inhibit complement activation in vivo. J. Immunol. 148: 3210-3215, 1992.
24. WEILER, J. M., YURT, R. W., FEARON, D. T. AND AUSTEN, K. F.: Modulation of the formation of the amplification convertase of complement, C3b, Bb, by native and commercial heparin. J. Exp. Med. 147: 409-421, 1978.
25. WEISMAN, H. F., BARTOW, T., LEPPO, M. K., MARSH, H. C., JR, CARSON, G. R., CONCINO, M. F., BOYLE, M. P., Roux, K. H., WEISFELDT, M. L. AND FEAEOH, D. T.: Soluble human complement receptor type 1: In vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necosis. Science (Wash. DC) 249; 146-151, 1990.
26. YASUDA, M., TAKEUCHI, K., HIRUMA, M., IIDA, H., TAHARA, A., ITAGANE, H., TODA, I., AKIOKA, K., TERAGAKI, M., OKU, H., YOSHIHAHU, K., TAKEDA, T., KOLB, W. P. AND TEMERIUS, J. D.: The complement system in ischemic heart disease. Circulation 81: 156-163, 1990.